Organization
National University Hospital
20 clinical trials
13 abstracts
Clinical trial
Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis: A Phase III Randomized Control Trial (Doxy-TB)Status: Recruiting, Estimated PCD: 2026-04-23
Clinical trial
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers: Phase 2 Randomized Trial (VALUE-CHECK)Status: Not yet recruiting, Estimated PCD: 2029-03-30
Abstract
Multi-ethnic genome-wide association study to identify a novel locus for susceptibility to immune-related adverse events from immune checkpoint inhibitors.Org: Department of Haematology Oncology, National University Cancer Institute Singapore, Department of Haematology-Oncology, Rheumatology Division, National University Hospital,
Clinical trial
An Open-label Phase II Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations Categorized According to Structural Based ClassificationStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Phase 1 Study of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel for Peritoneal Carcinomatosis - PIPAC2 StudyStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring Common EGFR Mutations Treated With AfatinibStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Ma-Spore ALL-Seq 2020: RNA-Seq and IgH/TCR-Seq to Improve Risk Assignment in Childhood, Adolescent and Young Adult Acute Lymphoblastic LeukaemiaStatus: Recruiting, Estimated PCD: 2030-03-01
Clinical trial
Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous Chimeric Receptor T Cells in HER2+ Advanced Breast Cancer and Other Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
DIRECT: Doxycycline Adjunctive Therapy to Reduce Excess Mortality and Complications From Central Nervous System Tuberculosis - Phase II Randomized Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2027-11-01
Clinical trial
Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic GliomaStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase I Dose Finding Study of Selinexor and Talazoparib in Patients With Advanced Refractory Solid Tumors, Followed by Phase II Expansion Cohort Study in Patients With Advanced/ Metastatic Triple Negative Breast Cancers. (START)Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL), First-in-man Phase 1 Safety TrialsStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Low-dose 500 mg Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer (mCRPC) and Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Patients: a Phase I Proof-of-concept Clinical StudyStatus: Active (not recruiting), Estimated PCD: 2023-09-05
Clinical trial
Phenotypic Personalized Medicine: Systematically Optimized Combination Therapy in Multiple Myeloma Using CURATE.AIStatus: Recruiting, Estimated PCD: 2025-09-10
Clinical trial
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Stage I-III HER2 Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2027-12-01
Clinical trial
Sequential Belimumab Followed by T-cell Based Therapy in the Treatment of Systemic Lupus Erythematosus (SUBTLE) - a Preliminary Proof-of-concept Mechanistic StudyStatus: Recruiting, Estimated PCD: 2025-05-20
Clinical trial
Personalised, Rational, Efficacy-driven Cancer Drug Dosing Via an Artificial Intelligence SystEm - CURATE.AI (PRECISE CURATE.AI Trial)Status: Recruiting, Estimated PCD: 2023-08-01
Clinical trial
Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin. Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin and in Combination With Nivolumab in Patients With Peritoneal Carcinomatosis (PIANO)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA MeasurementsStatus: Recruiting, Estimated PCD: 2023-05-31
Clinical trial
A Phase 1b Followed by Phase II Expansion Trial of Combination of Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer (ComPACT)Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase II Randomized Trial of Lenvatinib Combined With Letrozole Versus Fulvestrant in Metastatic Estrogen Receptor (ER) Positive, HER2 Negative Breast Cancer, Who Have Progressed on First-line Aromatase Inhibitor + a CDK4/6 Inhibitor.Status: Recruiting, Estimated PCD: 2025-08-01
Abstract
Real-world treatment patterns in patients with HER2+ unresectable or metastatic breast cancer: Interim results from HER2 REAL Asia cohort.Org: National University Hospital, National Cheng Kung University Hospital, Queen Elizabeth Hospital, Seoul National University Hospital, Westmead Hospital,
Abstract
Phase II study of trifluridine/tipiracil (FTD/TPI) in HER2-negative metastatic breast cancers with or without prior exposure to fluoropyrimidines.Org: Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, Saw Swee Hock School of Public Health, National University of Singapore,
Abstract
Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer.Org: Yong Loo Lin School of Medicine, National University of Singapore (NUS), Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, National University Cancer Institute, Mediclinic City Hospital,
Abstract
Mixed-methods clinical trial to evaluate the feasibility of the CURATE.AI optimised digital cognitive rehabilitation therapeutic (COR-Tx) in patients post brain radiotherapy.Org: The N.1 Institute for Health, The Institute for Digital Medicine (WisDM), National University of Singapore, Yale-NUS, National University Cancer Institute Singapore,
Abstract
Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Cornell University, National University Hospital, Department of Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University,
Abstract
Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.Org: University of Michigan Comprehensive Cancer Center, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, MSC National Research Institute of Oncology, Kraków, Poland, Sir Charles Gairdner Hospital,
Abstract
Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world.Org: National University Cancer Institute, National University Hospital, Icon Cancer Centre, NUHS,
Abstract
Value-driven colorectal cancer survivorship through partnership with primary care.Org: National University Cancer Institute, National University of Singapore, National University Hospital, National University Health Systems,
Abstract
Effects of Comprehensive Geriatric Assessment (CGA) guided care versus usual care on overall survival (OS) and health-related quality of life (HRQL) for older adults with cancer: A systematic review of randomized trials (RCTs).Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, National University Cancer Institute Singapore, National Registry of Diseases, Health Promotion Board, Department of Geriatric Medicine, The University of Tokyo, Tokyo, Japan,
Abstract
“ULTrA (URATE LOWERING THERAPY TO ACUTE TREATMENT RATIO)” – A PROPOSED NOVEL QUALITY INDEX TO DECREASE THE PREVENTABLE HEALTHCARE BURDEN OF GOUT IN AN ASIAN SOCIETYOrg: National University Hospital, Yong Loo Lin School of Medicine, National University Health Systems,
Abstract
ACHIEVING CONSENSUS IN ULTRASONOGRAPHY SYNOVITIS SCORING IN RHEUMATOID ARTHRITIS Org: National University Hospital, Tan Tock Seng Hospital, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center, Gleneagles Medical Centre, Singapore, Singapore,
Abstract
ASSOCIATION OF FLARES OF CONNECTIVE TISSUE DISEASE AND SYSTEMIC LUPUS ERYTHEMATOSUS WITH DRUG USE FOLLOWING COVID-19 MRNA VACCINATION: RESULTS FROM THE CORONAVIRUS NATIONAL VACCINE REGISTRY FOR IMMUNE DISEASES SINGAPORE (CONVIN-SING)Org: National University of Singapore, National University Hospital, Biostatistics Unit, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center, Duke-NUS Medical School,